Literature DB >> 34900844

Evaluation of phenoconversion phenomenon in obese patients: the effects of bariatric surgery on the CYP450 activity "a protocol for a case-control pharmacokinetic study".

Hengameh Ghasim1, Mohammadreza Rouini1, Kheirollah Gholami2, Farnoosh Larti3, Saeed Safari4, Yalda H Ardakani1.   

Abstract

Personalized therapy suggests the appropriate drug at the right dose for the first time through genotype-based individualized therapy, instead of prescribing medicines by the traditional one-size-fits-all manner, thereby claiming that it will make medicines safer and more effective. Accordingly, polymorphisms of drug metabolizing enzymes (DMEs), which induce inter-individual variability in the pharmacokinetics of a drug, have attracted great interest in the context of personalized medicine. Obesity is one of the most common chronic diseases in the world, including Iran, and the prevalence is increasing according to predictions. The remarkable role of P450 cytochromes has been verified in the metabolism of numerous drugs, toxins, carcinogen compounds, and the synthesis of some intrinsic compounds, such as steroid hormones. Thus, evaluating the activity of these enzymes is of great importance because any functionality variation can lead to failure in the treatment or unwanted side effects of some drugs. Therefore, any change in the activity of these enzymes in obese patients can also be problematic in the treatment process of these patients in comparison to normal weighted ones. Since only a few human studies have examined the role of inflammation in altering the function of these enzymes, it seems to be necessary to investigate the effect of obesity on the expression and activity of these enzymes; in which the role of inflammatory processes has been proven. Most importantly, it is worth evaluating changes in the activity levels of cytochrome P450 (CYP450) and the inflammatory cytokines after a course of post-surgical treatment and weight loss. To evaluate the activity of CYPs, a multi-drug cocktail is prescribed to obese patients before and after obesity surgery, as well as to healthy volunteers, to provide simultaneous evaluation of different isoforms. A complete demographic data, medical examinations, laboratory tests, and the CYPs genotype of all participants can be extremely important during this investigation. © Springer Nature Switzerland AG 2021.

Entities:  

Keywords:  Bariatric surgery; Cytochrome P450; Metabolism; Obesity; Personalized medicine; Phenoconversion

Year:  2021        PMID: 34900844      PMCID: PMC8630133          DOI: 10.1007/s40200-021-00852-w

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  24 in total

1.  Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction.

Authors:  A Färnert; A P Arez; A T Correia; A Björkman; G Snounou; V do Rosário
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jan-Feb       Impact factor: 2.184

Review 2.  Long-term pharmacotherapy considerations in the bariatric surgery patient.

Authors:  Christopher M Bland; April Miller Quidley; Bryan L Love; Catherine Yeager; Bliss McMichael; P Brandon Bookstaver
Journal:  Am J Health Syst Pharm       Date:  2016-06-28       Impact factor: 2.637

Review 3.  Implications of obesity for drug therapy: limitations and challenges.

Authors:  R Jain; S M Chung; L Jain; M Khurana; S W J Lau; J E Lee; J Vaidyanathan; I Zadezensky; S Choe; C G Sahajwalla
Journal:  Clin Pharmacol Ther       Date:  2011-06-01       Impact factor: 6.875

Review 4.  Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Drug Metab Dispos       Date:  2014-12-17       Impact factor: 3.922

5.  Modulation of CYP450 Activities in Patients With Type 2 Diabetes.

Authors:  Sophie Gravel; Jean-Louis Chiasson; Jacques Turgeon; Alexia Grangeon; Veronique Michaud
Journal:  Clin Pharmacol Ther       Date:  2019-07-09       Impact factor: 6.875

6.  CYP450 activities before and after Roux-en-Y gastric bypass: correlation with their intestinal and liver content.

Authors:  Célia Lloret-Linares; Youssef Daali; Chadi Abbara; Claire Carette; Jean-Luc Bouillot; Eric Vicaut; Sebastien Czernichow; Xavier Declèves
Journal:  Surg Obes Relat Dis       Date:  2019-05-20       Impact factor: 4.734

7.  Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.

Authors:  Marc Le Vee; Valérie Lecureur; Bruno Stieger; Olivier Fardel
Journal:  Drug Metab Dispos       Date:  2008-12-15       Impact factor: 3.922

8.  Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation.

Authors:  M Piquette-Miller; A Pak; H Kim; R Anari; A Shahzamani
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

9.  Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.

Authors:  Marija Bosilkovska; Caroline Samer; Julien Déglon; Aurélien Thomas; Bernhard Walder; Jules Desmeules; Youssef Daali
Journal:  Basic Clin Pharmacol Toxicol       Date:  2016-04-25       Impact factor: 4.080

10.  Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration.

Authors:  Joanna Porażka; Edyta Szałek; Wojciech Połom; Mateusz Czajkowski; Tomasz Grabowski; Marcin Matuszewski; Edmund Grześkowiak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.